Minnesota Mayo clinic retrospective, population study of RF & CCP in 1373 incident RA pts. At Dx, 37% dual seropositive, 13% +CCP only, 12% +RF only, & 38% seronegative. zDual seropositives had more erosions (31%) & flares (69% vs 51%). But +RF only highest mortality (adj 2.18) https://t.co/hPQewVgPoq

IXCHIQ - a live-attenuated chikungunya virus vaccine: 10-30% have mild-moderate adverse effects, w/ headache, fatigue, & myalgia. <3% have severe AEs. Rare reports of encephalitis in elderly post Ixchiq, due to type I IFN-neutralizing autoantibodies (same w/ yellow-fever Vax) https://t.co/3VlZCd4sGc

2026 SPARTAN Annual Meeting (May 14-16; Toronto) is now accepting abstract submissions! A premier mtg brings together cutting-edge researchers and teachers in spondyloarthritis (SpA). Submit your abstracts by Feb 1st!! https://t.co/IBXEkSxpDy https://t.co/cS7exDUc9H

Longitudinal study of 1761 US military service pre- & post-deployment. The prevalence of fibromyalgia in Males/Females was 2.%/2% (sames as civilians) but post-deploy incr to 8%/11% (P < 0.001). PTSD incr from 21% /18% to 23%/26%. PTSD predeployment lead to a 3 fold risk of FM. https://t.co/XTjuhjx0zd

Multinational retrospective review of CV risk in IIM (myositis) cohorts finds among 336 pts that > 1/3 are at moderate-high risk for CVD - but 34 % prescribed a statin. Moderate-high risk scores seen w/ necrotizing myopathy (OR 4.6), steroids (OR 1.8), dyslipidaemia (1.2) https://t.co/4IMiaHJvL3

DARWIN study ADHD med use among children and adults in Europe (Belgium, Germany, Netherlands, Spain, UK) more than doubled betw 2010 to 2023. IN UK use went up 20X in females, 15X males. (Ed. note: ADHD meds-->poor sleep-->fibromyalgia-->MSK pains) https://t.co/KlvUF1vhhj https://t.co/yEWXwM0WBL

Clinical contributors to pathogenesis and treatment outcomes for rheumatoid arthritis. Full read review of pathogenesis and unmet needs in #RA https://t.co/OZxOuXdnIq https://t.co/LuYoLVfb7N

Lupus Foundation announced today that US House of Representatives have approved $27 Million in Funding for Lupus Programs in 2026 w/ fund available from (CDC), OMH, & DoD. Funding increased 40% @ CDC, 33% @OMH, & $415 million @ National Institutes of Health https://t.co/ENcykcW7yA

Roche Canada announced that Health Canada has approved obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Following four initial doses in the first year, Gazyva can be administered twice yearly https://t.co/snAVErShjK

Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa

Emergencies, Independence & Hemorrhage (1.23.2026) Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow. https://t.co/l4iMADwA1A https://t.co/YB4mnb8Xlu

Testing for RF, CCP, ESR and CRP Check out the accompanying Advanced Practice Rheum: Rheumatoid and Inflammation Testing video. https://t.co/o1sle6CKg5 https://t.co/roYXcbPdBh

Advanced Practice Rheum: Methotrexate https://t.co/PHAFWBG4gJ https://t.co/p9cMqT4nhR

New content online: Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials https://t.co/nDxfWWgutC https://t.co/Z6JMojdBz4